Stephen Adler
Pulmonary Disease · Oklahoma City, OKNPI 1346349404
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,739 and has fallen 99.0% since, to $28 in 2024.
Across 269 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$744
- GSK$643
- AstraZeneca$429
- AbbVie$411
- Genentech USA, Inc.$397
- Sunovion Pharmaceuticals Inc.$299
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,450100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 45 | $744 |
| GSK | 48 | $643 |
| AstraZeneca(2 entities) | 19 | $429 |
| AbbVie(2 entities) | 19 | $411 |
| Genentech USA, Inc. | 19 | $397 |
| Sunovion Pharmaceuticals Inc. | 40 | $299 |
| Jazz Pharmaceuticals Inc. | 4 | $183 |
| Merck | 11 | $152 |
| Insmed, Inc. | 3 | $144 |
| Sanofi | 7 | $137 |
| Pfizer | 7 | $106 |
| Novartis | 7 | $103 |
| Regeneron Healthcare Solutions, Inc. | 5 | $95 |
| Shire North American Group Inc | 5 | $84 |
| Circassia Inc. | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Mylan Specialty L.p. | 4 | $53 |
| La Jolla Pharmaceutical Company | 2 | $48 |
| Advanced Respiratory, Inc | 2 | $35 |
| Johnson & Johnson | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Philips North America LLC | 1 | $22 |
| United Therapeutics Corporation | 2 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
| Electromed, Inc. | 1 | $13 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,453 in reported general payments places this provider in the 65th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.